Target Information

Target General Infomation
Target ID
T39977
Former ID
TTDC00103
Target Name
Macrophage migration inhibitory factor
Gene Name
MIF
Synonyms
GIF; Glycosylation-inhibiting factor; Phenylpyruvate tautomerase; MIF
Target Type
Clinical Trial
Disease Autoimmune diabetes [ICD10: E08-E13]
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25]
Refractory autoimmune diseases [ICD9: 279.4; ICD10: D84.9, M35.9]
Function
Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti- inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is notclear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.
BioChemical Class
Intramolecular oxidoreductases
Target Validation
T39977
UniProt ID
P14174
EC Number
EC 5.3.3.12
Sequence
MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALC
SLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA
Drugs and Mode of Action
Drug(s) Anti-MIF antibodies Drug Info Phase 4 Autoimmune diabetes [523659]
ISO-1 Drug Info Phase 1 Discovery agent [524984]
COR100140 Drug Info Preclinical Inflammatory disease [547879]
Inhibitor 3,4-Dihydroxycinnamic Acid Drug Info [551393]
3-(4-HYDROXY-PHENYL)PYRUVIC ACID Drug Info [551374]
4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME Drug Info [551374]
6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE Drug Info [551374]
Anti-MIF antibodies Drug Info [544220]
AVP-13546 Drug Info [529649]
AVP-13748 Drug Info [529649]
COR100140 Drug Info [550565]
ISO-1 Drug Info [535444]
NAPQI Drug Info [529649]
Pathways
KEGG Pathway Tyrosine metabolism
Phenylalanine metabolism
PathWhiz Pathway Tyrosine Metabolism
WikiPathways Spinal Cord Injury
Adipogenesis
References
Ref 523659ClinicalTrials.gov (NCT01452997) Evaluation of Anti-inflammatories in the Reduction of Bite Reactions. U.S. National Institutes of Health.
Ref 524984ClinicalTrials.gov (NCT02284919) [18F]ISO-1 PET/CT in Breast Cancer. U.S. National Institutes of Health.
Ref 547879Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020117)
Ref 529649MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9.
Ref 535444The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82. Epub 2002 May 7.
Ref 544220Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455.
Ref 550565Cortical Pty Ltd Presents MIF Antagonist Data at World Congress on Inflammation. Cortical Pty Ltd. 2005.
Ref 551374The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
Ref 551393How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.